Floatz logo

Valganciclovir

Lympho-proliferative Diseases

Viracta Therapeutics, Inc.Small moleculePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

28 Active assets in the Lympho-proliferative Diseases cohort.

Asset / SponsorPhaseRating
Darbepoetin Alfa
Mayo Clinic
Phase 3BB
Epoetin Alfa
Mayo Clinic
Phase 3BB
Fludarabine
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 2BB
Baclofen
Alliance for Clinical Trials in Oncology
Phase 3BB
Tabelecleucel
Pierre Fabre Medicament
Phase 3BB

View all 50 →

Same molecule, other indications

Valganciclovir is also rated in:

cytomegalovirus infectionDormant
BB
Indicative ·
68 / 100
View asset →
Epstein-Barr virus-associated lymphoproliferative disorderDormant
B
Indicative ·
61 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →